Bispecificity Enhances Effect
An effective drug for treatment of rheumatoid arthritis has been developed by researchers from Biotechnological Company BIOCAD.
It is a novel drug (ВСD-121), enabling interruption of negative effects of two proteins, as a bispecific monoclonal antibody.
According to Roman Ivanov, Vice-President for R&D and international business development of biotechnological company BIOCAD, bispecificity provides a synergistic effect, making the drug much more effective, compared to drugs targeted at the same proteins, but used in isolation.
According to forecasts of scientists the new drug, BCD-121, will help improve effectiveness of conventional therapy up to 75-80 per cent.